Medigene AG: Medigene announces change in executive leadership team

Planegg (pta028/31.08.2018/20:00 UTC+2) Medigene AG (FSE: MDG1, Frankfurt, Prime Standard, TecDAX), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the treatment of cancer announced today that the Chief Financial Officer (CFO), Dr. Thomas Taapken, will leave the Company for personal reasons and will resign from his CFO position effective August 31, 2018. His departure is not based on any disagreement with the Company's accounting principles or practices, internal controls, financial statement disclosures or research and development pipeline.

The members of the executive management team and the Company's finance team will assume the duties and responsibilities of the CFO office on an interim basis while the Company undertakes a search for its next CFO. In order to ensure a smooth transition, Dr. Taapken will continue to advise the Company as a consultant to the executive management board until the end of the year.

Dr. Taapken has served as the Company's CFO since the beginning of 2017, during which time the Company completed two successful capital increases with broad participation from international investors. Prof. Horst Domdey, the Chairman of the Supervisory Board of Medigene AG, stated: "On behalf of the Supervisory Board I want to thank Thomas for his significant contributions to Medigene as CFO." Prof. Dr. Dolores J. Schendel, Chief Executive Officer of Medigene AG added: "Thomas was highly committed to executing on the Company's corporate and financial strategy. Colleagues and employees owe him a great deal of respect and gratitude for his contributions. We wish Thomas all the best in his future endeavors."

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene focuses on the development of personalized T cell-based therapies, with projects currently in preclinical and clinical development.

For more information, please visit http://medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)

Emitter:	Medigene AG Lochhamer Straße 11 82152 Planegg Germany
Contact Person:	Medigene PR/IR
Phone:	+49 89 2000 33 3301
E-Mail:	investor@medigene.com
Website:	www.medigene.de
ISIN(s):	DE000A1X3W00 (Share)
Stock Exchange(s):	Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Hannover, Munich, Stuttgart, Tradegate